Literature DB >> 19857590

Pre-engraftment syndrome after double-unit cord blood transplantation: a distinct syndrome not associated with acute graft-versus-host disease.

Kevin J Patel1, Robert D Rice, Rebecca Hawke, Michelle Abboud, Glenn Heller, Andromachi Scaradavou, James W Young, Juliet N Barker.   

Abstract

Pre-engraftment syndrome (PES) occurring after cord blood transplantation (CBT) is poorly characterized. We reviewed 52 consecutive double-unit CBT recipients treated for high-risk hematologic malignancies. PES was defined as unexplained fever >38.3 degrees C (101 degrees F) not associated with infection and unresponsive to antimicrobials, and/or unexplained rash occurring before or at neutrophil recovery. CBT recipients (median age, 38 years; range, 3-66 years) received either myeloablative (MA; n=36) or nonmyeloablative (NMA; n=16) conditioning. Sixteen patients (31%) fulfilled PES criteria: 15 with fever (median at onset, 39 degrees C [102.2 degrees F]), 13 of whom also had rash, and 1 with rash alone. The median onset was 9 days (range, 5-12 days) posttransplantation (a median of 14 days before neutrophil recovery). Sixteen patients (14 with PES and 2 with infection and possible PES) received intravenous methylprednisolone (median dose, 1mg/kg; median duration, 3 days); 15 (94%) experienced resolution of fever within 24 hours. Recurrent PES (n=3) resolved with retreatment. There was no association between the development of PES and the likelihood of sustained donor engraftment, speed of neutrophil recovery, grade II-IV acute graft-versus-host disease (aGVHD), day-180 treatment-related mortality (TRM), or survival. PES is common after CBT, precedes neutrophil recovery, is distinct from and does not predict for aGVHD, and responds promptly to short-course corticosteroid therapy. Copyright (c) 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19857590      PMCID: PMC3096002          DOI: 10.1016/j.bbmt.2009.10.022

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  17 in total

1.  Engraftment syndrome after autologous peripheral blood stem cell transplantation with high numbers of peripheral blood stem cells followed by granulocyte colony-stimulating factor administration.

Authors:  C Kawano; K Muroi; R Kuribara; Y Matsumoto; T Ohtsuki; K Hatake; K Ozawa
Journal:  Bone Marrow Transplant       Date:  2000-01       Impact factor: 5.483

Review 2.  Engraftment syndrome following hematopoietic stem cell transplantation.

Authors:  T R Spitzer
Journal:  Bone Marrow Transplant       Date:  2001-05       Impact factor: 5.483

3.  Clinical evidence for an engraftment syndrome associated with early and steep neutrophil recovery after autologous blood stem cell transplantation.

Authors:  C Ravoet; W Feremans; B Husson; F Majois; A Kentos; M Lambermont; G Wallef; P Capel; M Beauduin; A Delannoy
Journal:  Bone Marrow Transplant       Date:  1996-11       Impact factor: 5.483

4.  Increased frequency of autoaggression syndrome associated with autologous stem cell transplantation in breast cancer patients.

Authors:  J S Moreb; P S Kubilis; D L Mullins; L Myers; M Youngblood; C Hutcheson
Journal:  Bone Marrow Transplant       Date:  1997-01       Impact factor: 5.483

5.  Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning.

Authors:  Juliet N Barker; Daniel J Weisdorf; Todd E DeFor; Bruce R Blazar; Jeffrey S Miller; John E Wagner
Journal:  Blood       Date:  2003-05-08       Impact factor: 22.113

6.  Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival.

Authors:  John E Wagner; Juliet N Barker; Todd E DeFor; K Scott Baker; Bruce R Blazar; Cindy Eide; Anne Goldman; John Kersey; William Krivit; Margaret L MacMillan; Paul J Orchard; Charles Peters; Daniel J Weisdorf; Norma K C Ramsay; Stella M Davies
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

7.  High incidence of human herpesvirus 6 infection with a high viral load in cord blood stem cell transplant recipients.

Authors:  Junji Sashihara; Keiko Tanaka-Taya; Shinya Tanaka; Kiyoko Amo; Hiromi Miyagawa; Gaku Hosoi; Tomokuni Taniguchi; Takafumi Fukui; Naoki Kasuga; Toshiya Aono; Masahiro Sako; Junichi Hara; Koichi Yamanishi; Shintaro Okada
Journal:  Blood       Date:  2002-09-15       Impact factor: 22.113

8.  Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation.

Authors:  R Schots; L Kaufman; I Van Riet; T Ben Othman; M De Waele; B Van Camp; C Demanet
Journal:  Leukemia       Date:  2003-06       Impact factor: 11.528

9.  Engraftment syndrome in autologous bone marrow and peripheral stem cell transplantation.

Authors:  C K Lee; R D Gingrich; R J Hohl; K A Ajram
Journal:  Bone Marrow Transplant       Date:  1995-07       Impact factor: 5.483

10.  Engraftment syndrome following autologous hematopoietic stem cell transplantation: definition of diagnostic criteria.

Authors:  A Maiolino; I Biasoli; J Lima; A C Portugal; W Pulcheri; M Nucci
Journal:  Bone Marrow Transplant       Date:  2003-03       Impact factor: 5.483

View more
  14 in total

1.  Engraftment Syndrome and Acute Graft-versus-Host Disease: A Meta-Analysis.

Authors:  Kittika Poonsombudlert; Jakrin Kewcharoen; Chattip Prueksapraopong; Nath Limpruttidham
Journal:  Hawaii J Health Soc Welf       Date:  2020-06-01

2.  Monitoring mycophenolate mofetil is necessary for the effective prophylaxis of acute GVHD after cord blood transplantation.

Authors:  Y Arai; T Kondo; T Kitano; M Hishizawa; K Yamashita; N Kadowaki; T Yamamoto; I Yano; K Matsubara; A Takaori-Kondo
Journal:  Bone Marrow Transplant       Date:  2014-11-10       Impact factor: 5.483

Review 3.  Engraftment syndrome: double-edged sword of hematopoietic cell transplants.

Authors:  T R Spitzer
Journal:  Bone Marrow Transplant       Date:  2015-01-12       Impact factor: 5.483

Review 4.  Allogeneic reactivity-mediated endothelial cell complications after HSCT: a plea for consensual definitions.

Authors:  Simona Pagliuca; David Michonneau; Flore Sicre de Fontbrune; Aurélien Sutra Del Galy; Aliénor Xhaard; Marie Robin; Régis Peffault de Latour; Gérard Socie
Journal:  Blood Adv       Date:  2019-08-13

Review 5.  Optimal Practices in Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies.

Authors:  Juliet N Barker; Joanne Kurtzberg; Karen Ballen; Michael Boo; Claudio Brunstein; Corey Cutler; Mitchell Horwitz; Filippo Milano; Amanda Olson; Stephen Spellman; John E Wagner; Colleen Delaney; Elizabeth Shpall
Journal:  Biol Blood Marrow Transplant       Date:  2017-03-06       Impact factor: 5.742

6.  Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulin.

Authors:  Craig Sauter; Michelle Abboud; Xiaoyu Jia; Glenn Heller; Anne-Marie Gonzales; Marissa Lubin; Rebecca Hawke; Miguel-Angel Perales; Marcel R van den Brink; Sergio Giralt; Genovefa Papanicolaou; Andromachi Scaradavou; Trudy N Small; Juliet N Barker
Journal:  Biol Blood Marrow Transplant       Date:  2011-03-01       Impact factor: 5.742

7.  Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment.

Authors:  Elizabeth O Hexner; Selina M Luger; Ran Reshef; Grace R Jeschke; James K Mangan; Noelle V Frey; Dale M Frank; Lee P Richman; Robert H Vonderheide; Nicole A Aqui; Misha Rosenbach; Yi Zhang; Anne Chew; Alison W Loren; Edward A Stadtmauer; Bruce L Levine; Carl H June; Stephen G Emerson; David L Porter
Journal:  Am J Hematol       Date:  2016-04-04       Impact factor: 10.047

8.  Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment.

Authors:  J Kanda; L Kaynar; Y Kanda; V K Prasad; S H Parikh; L Lan; T Shen; D A Rizzieri; G D Long; K M Sullivan; C Gasparetto; J P Chute; A Morris; S Winkel; J McPherson; J Kurtzberg; N J Chao; M E Horwitz
Journal:  Bone Marrow Transplant       Date:  2013-01-21       Impact factor: 5.483

9.  Engraftment syndrome after allogeneic hematopoietic cell transplantation predicts poor outcomes.

Authors:  Lawrence Chang; David Frame; Thomas Braun; Erin Gatza; David A Hanauer; Shuang Zhao; John M Magenau; Kathryn Schultz; Hemasri Tokala; James L M Ferrara; John E Levine; Pavan Reddy; Sophie Paczesny; Sung Won Choi
Journal:  Biol Blood Marrow Transplant       Date:  2014-06-02       Impact factor: 5.742

10.  Pulmonary manifestations of the pre-engraftment syndrome after umbilical cord blood transplantation.

Authors:  Kyle R Brownback; Steven Q Simpson; Joseph P McGuirk; Tara L Lin; Sunil Abhyankar; Siddhartha Ganguly; Omar S Aljitawi
Journal:  Ann Hematol       Date:  2013-12-18       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.